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Abstract
Background:  There has been increasing concern regarding the potential effects of the
commercialization of research.
Methods: In order to examine the relationships between funding source, trial outcome and
reporting quality, recent issues of five peer-reviewed, high impact factor, general medical journals
were hand-searched to identify a sample of 100 randomized controlled trials (20 trials/journal).
Relevant data, including funding source (industry/not-for-profit/mixed/not reported) and statistical
significance of primary outcome (favouring new treatment/favouring conventional treatment/
neutral/unclear), were abstracted. Quality scores were assigned using the Jadad scale and the
adequacy of allocation concealment.
Results:  Sixty-six percent of trials received some industry funding. Trial outcome was not
associated with funding source (p= .461). There was a preponderance of favourable statistical
conclusions among published trials with 67% reporting results that favored a new treatment
whereas 6% favoured the conventional treatment. Quality scores were not associated with funding
source or trial outcome.
Conclusions: It is not known whether the absence of significant associations between funding
source, trial outcome and reporting quality reflects a true absence of an association or is an artefact
of inadequate statistical power, reliance on voluntary disclosure of funding information, a focus on
trials recently published in the top medical journals, or some combination thereof. Continued and
expanded monitoring of potential conflicts is recommended, particularly in light of new guidelines
for disclosure that have been endorsed by the ICMJE.
Background
There has been increasing concern regarding the potential
effects of the commercialization of research [1–5]. This
concern has coincided with the reduced availability of
public research funds which has, in turn, translated to sci-
entists' increased reliance on industry support. For exam-
ple, in the United States, approximately 70% of clinical
drug trials are now funded by industry [2]. Industry fund-
ing of biomedical research can be viewed as a conflict of
interest because the sponsor of the study has a vested fi-
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nancial interest in its outcome. Since even the perception
of a conflict can undermine the public's trust, due dili-
gence, in the form of recognizing and managing potential
conflicts, is warranted.
This is not to suggest that industry abandon its sponsor-
ship of biomedical research. Indeed, many medical dis-
coveries may not have occurred without industry funding.
Nevertheless, fundamental errors have been noted in the
design of industry-funded trials [6]. These methodologi-
cal deficiencies, perhaps operating in conjunction with
the well-documented phenomenon of publication bias,
have led to a preponderance of published trials that have
received funding from for-profit entities and whose con-
clusions favour industry [7–16].
Concern over the increasing commercialization of re-
search also extends to the quality of reporting. Low quality
reports have been noted among published trials [6,17]
and reports of low quality trials have been found to exag-
gerate an intervention's effectiveness [16,18]. Because re-
lationships between funding source, trial outcome and
reporting quality may bias study results, making informed
decision making about the merits of an intervention more
difficult for clinicians and consumers alike, it is important
to examine the extent to which a trial's source of funding
influences its results.
Methods
A convenience sample of 100 randomized controlled tri-
als (RCTs) was identified by hand-searching recent issues
of five peer-reviewed, high impact factor general medical
journals (Annals of Internal Medicine, British Medical Jour-
nal, Journal of the American Medical Association, The Lancet,
The New England Journal of Medicine). Issues published be-
tween January 1999 and October 2000 were searched un-
til 20 RCTs/journal were identified. To be eligible for
inclusion, the RCT needed to be published as a full report.
Interventions were restricted to pharmaceuticals; medical
devices, surgical procedures and methods of medical
management (e.g., lifestyle counseling) were excluded.
No attempts were made to limit the selection to any par-
ticular RCT design, number of treatment arms, compara-
tor (e.g., placebo, active control, alternate dosing, herbal
therapy), study population or disease category.
Relevant data, including funding source(s) and primary
outcome, were abstracted from each eligible RCT. Report-
ing quality was assessed using both a composite (overall
score on the Jadad scale [19]) and a component (individ-
ual items on Jadad scale and adequacy of allocation con-
cealment [20]) approach. The Jadad scale consists of a
total of five items; two items relate to blinding, two items
relate to randomization and one item assesses the descrip-
tion of withdrawals/drop-outs. When using the Jadad
scale to score the quality of a trial report, each of the five
items receives a "yes" or a "no," resulting in an overall/
composite quality score that can range from 0 to 5; higher
scores reflect better methodological quality [19].
Allocation concealment was rated as adequate, inade-
quate or unclear in the manner proposed by Schulz et al
[20]. Allocation concealment refers to the process that
prevents foreknowledge of treatment assignment and
thus, shields those who enroll participants from being in-
fluenced by this knowledge. For example, a trial was rated
as having "adequate" concealment if allocations were per-
formed using central randomization; numbered/coded
bottles/containers; serially numbered, opaque, sealed en-
velopes or if the formulations were prepared by a pharma-
cy. Allocation was classified as "inadequate" if
assignments were made on an alternating basis or via ref-
erence to case record number or date of birth. Trials that
received an "unclear" rating would have failed to provide
sufficient information regarding the allocation process on
which to base our decision. In all cases, reporting quality
was evaluated by two independent, experienced reviewers
(DM, TC). No formal training was conducted prior to
evaluating the RCTs using either of the quality assessment
scales since both raters have extensive experience using
these methods. Moreover, since any disagreements in
quality ratings were resolved by consensus, we did not un-
dertake assessment of inter-rater reliability.
In order to examine the relationship between trial out-
come, funding source and reporting quality, SPSS-PC soft-
ware was used to conduct statistical analyses in the form
of Fisher's exact test or ANOVAs, as appropriate. The odds,
and corresponding 95% confidence intervals, of unclear
allocation concealment, by funding source and trial out-
come, are also presented.
Trials were classified according to their funding source(s)
in a manner similar to that used by Rochon [17], permit-
ting comparison of trials across four levels of funding: en-
tirely industry, entirely not-for-profit, mixed and not
reported. A trial was classified as having "mixed" funding
if it received support from at least one industry source and
at least one not-for-profit source. Because this study was
restricted to RCTs that examined pharmaceuticals, indus-
try funding is synonymous with pharmaceutical company
funding.
The primary outcome was defined as the one stated as
such by the authors or, if there was no such statement, the
one that was most clinically relevant (i.e., mortality over
morbidity). If one outcome was not more clinically rele-
vant than the others, the outcome contributing the most
patients was used. On the basis of statistical interpretation
of results, rather than reliance on authors' interpretationsBMC Health Services Research 2002, 2 http://www.biomedcentral.com/1472-6963/2/18
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presented in discussion/conclusion sections, the outcome
of trials was classified as favoured new treatment, fa-
voured conventional treatment, neutral (i.e., non-signifi-
cant) or unclear.
Results
Of the 100 trials reviewed, sixty-six were funded in whole
or in part by industry; 6 did not disclose their source of
funding. Of these same 100 trials, 67 favoured the new
therapy, 6 favoured the conventional treatment, 19 re-
ported neutral findings while, in eight cases, the outcome
was classified as unclear owing to ambiguity between the
defined outcome of interest and data presented in the re-
sults section. Results for reporting quality varied accord-
ing to the dimensions of quality that were measured: the
overall/composite score on the Jadad scale indicated that
74% of the trials were of higher quality (scores of 3–5)
with a mean score of 3.31 (SD 1.19) while allocation con-
cealment was found to be unclear in close to 60% of trials.
The results of bivariable analyses examining associations
between allocation concealment and funding source and
between allocation concealment and trial outcome are
presented in Table 1. Odds ratios and corresponding 95%
CI for these associations are also presented. Data reflect-
ing the comparison between funding source and trial out-
come are presented in Table 2. In none of these cases were
the associations found to be statistically significant. A
one-way ANOVA also failed to demonstrate statistical sig-
nificance between the overall/composite score on the Ja-
dad scale, measured as a continuous variable, and funding
source (F = 1.853; df = 3; p = .143), trial outcome (F =
1.003; df = 3; p =.395) and allocation concealment (F =
1.319; df = 2; p = .272). The absence of a statistically sig-
nificant association between reporting quality and fund-
ing source and between reporting quality and trial
outcome persisted when individual components of the Ja-
dad scale (i.e., blinding, randomization, and description
of withdrawals/drop-outs) were examined.
Discussion
The results of this pilot study failed to document any as-
sociation between funding source, trial outcome and re-
porting quality among a sample of RCTs that were
recently published in the top five general medical jour-
nals. It is not known whether this finding (which has been
Table 1: Allocation concealment by funding source and by trial outcome
Adequate Inadequate Unclear Total OR* (95% CI)
By Funding Source:
Industry Only 16 1 27 44 1.00 (ref)
Not for Profit Only 13 2 13 28 .55 (.21, 1.42)
Mixed + 6 1 15 22 1.35 (.46, 3.98)
Not Reported 1 1 4 6 1.26 (.21, 7.64)
Total 36 5 59 100
p = .377
By Direction and Statistical Significance of Trial Outcome:
Favoured New 21 4 42 67 1.00 (ref)
Favoured Conventional 4 0 2 6 .24 (.04, 1.32)
Neutral 7 1 11 19 .82 (.29, 2.31)
Unclear 4 0 4 8 .79 (.16, 3.84)
Total 36 5 59 100
p = .678
*OR = odds ratio of unclear allocation concealment, relative to clear (i.e., adequate or inadequate); + = funding by at least one industry source and 
at least one not-for-profit sourceBMC Health Services Research 2002, 2 http://www.biomedcentral.com/1472-6963/2/18
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observed by some [16,21] but not by others
[7,13,15,22,23]) reflects a true absence of an association
or, instead, represents an artefact, due to limitations in-
herent in this, a pilot study.
For example, our failure to detect any significant associa-
tions may result from a type 2 error that indicates inade-
quate statistical power. Although our results do not even
hint at a trend (and, perhaps, reflect the emphasis now
placed on disclosure at the journals included in our sam-
ple [24]), the potential for type 2 error is real, as suggested
by the width of the confidence intervals presented in Ta-
ble 1. Our estimates of association were based on a sam-
ple size that, while relatively small, is typical of the initial
phases of a program theme, such as that upon which we
were embarking; future works will accrue larger samples
to reduce the likelihood of this error.
Admittedly, the limitations of our study extend beyond is-
sues of statistical power. For example, we depended on au-
thors' disclosure of a trial's funding source(s) and the
subsequent publication of this information. Recent work
suggests that failure to disclose personal financial conflicts
is widespread [4]. Although this is different than reporting
a trial's source of funding, it supports the notion that fail-
ure to abide by journal disclosure requirements is com-
mon. Moreover, since journals, themselves, do not always
abide by their own disclosure rules [1,4], our categoriza-
tion of funding source(s) may be biased.
In addition, because this study focussed on recent publi-
cations of the top five general medical journals, our results
may not generalize to journals that differ in their impact
factor, disclosure requirements and/or reporting policies.
It is important that our results be viewed in this context,
particularly since some research suggests that researchers
submit their "best" work to the "best" journals [25,26].
Future research, relying on a modified design that has
been used to address similar questions [18,20,27] might
allow more comprehensive exploration of these relation-
ships. For example, future works, accruing a larger sample
of RCTs from a wider variety of journals, should adjust for
covariates (e.g., number of sites involved, number of treat-
ment arms, sample size) in multivariable models and may
find it fruitful to examine statistical outcomes in the con-
text of effect size.
It is also possible that the discordance seen between our
findings and others [7,13,15,22,23] stems, in whole or in
part, from differences in the operational definition of "in-
dustry-sponsored research." More specifically, some
[7,13,15,22] have categorized RCTs that receive any indus-
try funding to be "industry-sponsored" and have com-
pared this category with those RCTs that are wholly
funded by not-for-profit monies. In our study, we treated
RCTs that received funding from one or more corporate
sponsor and one or more not-for-profit sponsor as receiv-
ing "mixed funding" while the category "industry only"
was reserved for those RCTs that did not receive any not-
for-profit funds. It is important that authors acknowledge
the potential for differences in operational definitions of
funding source between studies to produce discordant re-
sults; this can be best accomplished by ensuring that the
scheme for classifying trials according to their funding
source(s) be made explicit in each report.
As a result of these limitations, we are unable to conclude,
with a high degree of confidence, that the absence of an
association between funding source, trial outcome and re-
porting quality that was documented in this study reflects
Table 2: Funding source by trial outcome
Funding Source
Direction and Statistical
Significance of Trial Outcome
Industry ONLY Not for Profit ONLY Mixed + Not Reported TOTAL
F a v o u r e d  N e w 3 0 1 5 1 666 7
Favoured Conventional 4 1 1 0 6
Neutral 6 9 4 0 19
Unclear 4 3 1 0 8
Total 44 28 22 6 100
p = .461
+ = funding by at least one industry source and at least one not-for-profit sourceBMC Health Services Research 2002, 2 http://www.biomedcentral.com/1472-6963/2/18
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a benefit of strengthened disclosure requirements at the
top general medical journals. Our results do, however,
suggest the benefits of one particular standardized report-
ing requirement, CONSORT [28]. Endorsement of CON-
SORT by the International Committee of Medical Journal
Editors (ICMJE) [29] may have contributed to the major-
ity (~75%) of trial reports receiving moderate-high quality
composite scores on the Jadad scale. This has not always
been the case, with almost uniformly poor quality found
amongst trials published prior to widespread adherence
to CONSORT [14,17–20,30]. There is still room for im-
provement, however. Recent revisions to CONSORT and
its adoption by increasing numbers of journals should ad-
dress the alarming dominance of "unclear" allocation
concealment seen among trials examined in this report
and elsewhere [9,20,30–34]. The persistence of a prepon-
derance of trial reports favoring novel treatments
[7,8,10,12,21,35], however, remains a challenge.
Conclusion
Concerted and continued efforts to monitor the reporting
quality of RCTs, to ascertain the best method(s) for its
evaluation [36] and to encourage the mandatory registra-
tion of trials [8,10,12,37–39] are recommended. Given
that the ICMJE recently strengthened its requirement for
disclosure of information as to the role(s) of study spon-
sor(s) in all aspects of study design, conduct and publica-
tion [24] while, at the same time, the New England Journal
of Medicine has announced that they will be relaxing their
longstanding rules on conflict of interest [40], the ques-
tion posed by this study should be revisited to allow for
more definitive determination of the impact of industry
sponsorship on biomedical research. We encourage jour-
nal editors to continue to work together in order to reach
consensus as to the particulars of reporting requirements.
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